Year ender 2025: From Ozempic to Yeztugo; key new drug approvals in 2025 and why they matter

This year’s medicines demonstrate that research, resilience and a touch of serendipity can alter the course of treatment. (Picture Credit: Canva) (Picture Credit: Pexels)

Who could have thought that medicines and vaccines, and not just surgery, could help fight dangerous diseases. However, here we are. Come 2025, and things seemed to change. Now, diabetes injection could also protect kidneys, andHIV prevention would need only two shots a year. The FDA and global regulators have delivered a series of approvals this year that reflect not just scientific ingenuity, but human need, dealing with stubborn diseases with fresh hope and, importantly, evidence.

Medicine isn’t just about pills and injections any more; it’s about improving lives in ways we dared dream about only a decade ago. Here are some of the medicines that matter because their benefit isn’t confined to lab reports, patients feel it, clinicians prescribe it, and epidemiologists note shifts in outcomes.

Ozempic’s broader reach beyond blood sugar

This familiar, or should we say viral, name took on an expanded role in 2025, when semaglutide (Ozempic) gained approval to reduce the progression of chronic kidney disease and cut the risk of cardiovascular death in adults with type 2 diabetes; transforming a diabetes staple into an organ‑protective therapy backed by phase 3b FLOW trial evidence.

Journavx (suzetrigine), non‑opioid acute pain

After decades with little change, suzetrigine, marketed as Journavx, won FDA approval as the first new class of non‑opioid acute pain medicine in more than twenty years. Its targeted sodium channel blocking shows meaningful relief without the dependence risks that have plagued pain management.

Also read: Treadmill running vs running outdoors: Fitness coach shares which one is best for you

Neffy nasal spray makes anaphylaxis easier to treat

In paediatric allergy care, the newly approved epinephrine nasal spray (neffy) represents a step change. Studies showed it performs on par with injectable versions, but without the needle, a small thing that matters hugely when minutes count.

Yeztugo (lenacapavir), a shot at HIV prevention

Gilead’s twice‑yearly injectable lenacapavir, brand name Yeztugo, has reshaped the landscape for HIV pre‑exposure prophylaxis (PrEP). Clinical trials showed near‑total reduction in HIV transmission compared with daily pills, offering simplicity and adherence that could bend the curve of a decades‑old epidemic.

Dupixent for bullous pemphigoid

Until recently, bullous pemphigoid, a blistering autoimmune skin disease, had few good options. Dupilumab (Dupixent) became the first targeted therapy approved for this condition after trials demonstrated stronger remission and itch reduction versus placebo, easing suffering for thousands.

Blujepa tackles drug‑resistant infection

In a rare but important leap for antibiotics, Blujepa (gepotidacin) secured approval as a new oral treatment for uncomplicated gonorrhoea, a bacterial foe growing alarmingly resistant to existing drugs. Clinics now have another weapon in fighting STI‑linked complications.

Why 2025 felt different

What makes 2025 extraordinary isn’t just the number of approvals, but the impact they promise. We’ve seen chronic diseases managed more holistically, pain treated without old pitfalls, and preventive medicine reach new heights. From children with allergies to adults at risk of kidney failure, the story isn’t just about science, it’s about humanity. This year’s medicines demonstrate that research, resilience and a touch of serendipity can alter the course of treatment.

Also read: Sleeping for less than 6 hours every night? Doctors have a warning that you must not ignore

Disclaimer: This article, including health and fitness advice, only provides generic information. Don’t treat it as a substitute for qualified medical opinion. Always consult a specialist for specific health diagnosis.